Member Info for FatherTedCrilly

Likely the deal has already been done… I’d expect an RNS to that effect later today or tomorrow

That clause is protect RF... so that they don't have to honour the terms of the agreement if there is no market to sell their share into (i.e. the share price has crashed so much that they can't offload).

I think the true horror of this 'financial' arrangement is becoming apparent

There seems to be a clause in the Riverfort agreement that prevents the final funding tranche if funding exceeds 10% of the market cap?

To me this is unclear as to overall funding or a single tranche… but given the direction of the SP some clarity might be needed. FFS.

Apologies if already posted - I’m not on the boards as much recently…

But hvivo still have a 50% stake in this if I’m not mistaken (this being AGS-v)

https://www.news-medical.net/news/20240131/New-project-aims-to-increase-the-EUs-ability-to-combat-flavivirus-threats.aspx

https://conservbio.com/news/project-to-improve-global-flavivirus-defence-kicks-off/

I always saw more potential in this than Flu-v and had hopes that CF might drive it forward…

Great to see it being developed, but as there are universities involved I suspect it will move at the speed of ar5e.

If I have time I’ll dig out my old notes and try and summarise why I was so excited about this commercially.

This may have been listed on the accounts as ‘nil value’ but I believe it is potentially very valuable.

GLA, Ted

Thanks for the kind words SoundMan.

I haven't been so active on the boards recently as life has become very busy (in a good way) . I'm going to try and check-in a bit more regular though, as I think 2024 will be a very productive year for both HVO and POLB.

The best of luck to you too...

I sold my initial Poolbeg holding… but bought in heavily when the price hit 4/5p on nothing more than tough market conditions. I’ve continued to buy sub 10p and this is now my largest holding. I will likely add a few more as and when I close other positions. It is for stocks like this that I play around with aim (note: I don’t count Hvivo as a typical aim stock - that one is a very rare gem).

Because phase 3 trial are f'ing expensive and who would take the risk without phase 2 data.

J3sus wept

“It is quite normal if a CFO resigns for them to leave immediately”

🤣🤣🤣🤣🤣

"why the negativio on a Saturday evening at past 10.00pm"

I was responding to a post at 19:17 on a Saturday evening. Why is the time of posting important?

"Think you know the reason"

I don't, and likely no-one outside of the Sareum board and advisors do... My assumption is that this is the only money they could get.

The CFO resigning with no notice is ‘a storm in a teacup’? Seriously?

Shareholders need to hope that this is an issue with the CFO and not the company finances? Clarity is needed… silence does not look good. Will there be an RNS explaining on Monday?

Then why are SAR currently using the finance of last resort (Riverfort)?

I agree Cashintime, there has been some decent buying in recently (I've also added to my holding).

If any of POLB's products become cash generative then there will be a significant bounce. If it happens to be POLB-001, in the cancer space, then I think we are looking at multiples.

The Amryt team have come on board for a reason. I'm excite and optimistic and will continue to add below 10p. GLA

Given that the phase 1a trial started on June the 6th 2023, and there has been no negative news, is positive safety data now priced in?

That would be seriously depressing :-/

Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854317/

Interesting reading.

Obviously, there are no guarantees... but I'm very happy to be invested in this space.

(if you don't fancy reading the whole article, Table one breaks down average valuations)

This is the key word.

POLB-001 has already demonstrated safety in a human challenge trial - now we know it works for CRS in animal studies.

We are now very well placed for a partnership / deal to take this forward into Phase 2.

What a great start to the day :-)

FLU-v doesn't really fit into POLB's business model (pre clinical and early clinical). It is Phase 3 ready and will likely need large pharma or an investment led vehicle to take it to market (i.e. it will need a lot of cash).

AGS-v might well conduct a phase 2 trial with Hvivo (there are obvious synergies there) but I can't see involvement passed that. They are both great assets to have a stake in - but others will fund their development.

(this is not in anyway meant to be negative... I'm interested in both products - and hugely optimistic about AGS-v's potential :-)

Good find Nathan - thanks for sharing.

Hi BillB

I've also started buying in. This has been on my watch list for a long time - and the current price seems seriously good value (coming down 50% on nothing more than tough market conditions seems massively overdone to me).

The director buys have given me added confidence.

An Institutional investor (or individual) that was waiting for the patent issue to be resolved before buying in?

Regardless, it is nice to see some chunky buying :-)

If that is the Michael Kelley who has bought into POLB... then maybe a NASDAQ (dual) listing is coming?
:-)